

Olainfarm – Your Path To Pharmaceutical  
and Chemical Excellence

---



**Your health is our  
passion!**

[www.olainfarm.com](http://www.olainfarm.com)

**One of the Leading Pharmaceutical companies in the Baltic Region** with 50+ years of industry experience

### Diverse Product Portfolio:

60 stock keeping units, 19 active pharmaceutical substances, and 14 intermediates, covering essential therapeutic areas. Product portfolio is continuously developed and expanded.

### Advantages of Choosing Olainfarm:

- **Reliable Supply Chains:** we ensure consistent product availability to meet market demand.
- **Cost Efficiency:** advantages from lower labor costs, efficient production processes and regionally developed logistics.
- **High-Quality Standards:** adherence to the highest industry quality and safety standards.
- **Sustainability:** recognized for sustainability efforts, including a solar panel park to provide 40% of our energy by end of 2024.

### Future Plans:

At least 100 million euros investment for 5 years to drive innovation and sustainability.

### Commitment to Success:

Choose Olainfarm for a financially stable partner, including an out-licensing one, with extensive therapeutic expertise and a focus on building long-term, successful relationships.

# Olainfarm is a part of the AB City group

2<sup>nd</sup> most valuable local private capital holding in Latvia (748 mn. EUR in 2021)

Holding includes Baltic market leaders in healthcare providers, wholesale, manufacturing, laboratory examination services, and pharmacy chains etc.


\* Figures provided are for December 2022, unless stated otherwise



# Olainfarm in key facts & figures



120,25 mn EUR  
neto consolidated turnover,  
2022




> 1 billion  
production capacity for  
tablets and capsules per  
year



8,1 mn EUR  
investment in R&D,  
2022



840 professional employees  
in Olainfarm and more than 1400  
employees in the Olainfarm group



48 ha  
area of the company  
in Olaine



Golden Award  
National Sustainability Index,  
2023

# Experienced and professional management team



**Juris Bundulis**

Chairman of the Board

Juris brings decades of experience in leading major pharmaceutical companies in the Baltics and has a distinguished background in high-level government administration. He joined Olainfarm in 2021 as the Chairman of the Supervisory Board, and since September 2022, he has held the position of Chairman of the Board. Prior to that, he held prominent positions in other healthcare companies and possesses extensive experience in public administration. Juris has doctoral degrees in both chemistry and biology.



**Jānis Leimanis**

Board Member, CFO

Jānis is a finance professional with extensive experience in business and finance. He has been a board member of Olainfarm since June 2021, overseeing financial matters. Previously Jānis has worked in asset management, financial services, and leadership roles in both public and private sectors. He holds a bachelor's degree in mechanics and Mini MBA.



**Andris Jegorovs**

Board Member, CPO

Andris is a pharmaceutical professional with over 35 years of experience. He has been a board member of Olainfarm since September 2022 and has been the Production Director since 2021. Andris holds degrees in chemical technology and an MBA, and he is an industry expert with significant contributions to the Latvian Chemical and Pharmaceutical Industry Association (LAĶĪFA) and other NGOs.



**Raimonds Terentjevs**

Director of Quality Management Department

Raimonds, with over 20 years of experience in the chemical and pharmaceutical sectors, serves as the Director of Quality Management at Olainfarm since 2011, having previously worked as a researcher at the Latvian Institute of Organic Synthesis. Raimonds holds both bachelor's and master's degrees in chemistry.



**Elena Bushberg**

Executive Director

Elena has over 25 years of experience in international pharmaceutical companies. Her skills include strategy development, leading transformation, and fostering a culture of efficiency. She holds a Global Executive MBA from Duke University – The Fuqua School of Business. Since 2020, she has served as the Executive Director at Olainfarm.



**Ēriks Ivanovskis**

Director of Scientific Office

Ēriks is a seasoned professional with over 25 years of experience in pharmaceutical development, including leadership roles in FDF and API development, regulatory affairs, and contract research and development. He holds a Master's degree in Pharmacy and a Master's degree in Chemistry. Currently serving as the Scientific Office Director at Olainfarm since September 2022.



**Viktorija Zefirova-Tačinska**

Change and Development Process Manager

Viktorija brings extensive healthcare management experience, spanning international and Latvian firms and the public sector. With expertise in change management and corporate culture transformation, she holds an MBA from Riga Technical University and a cardiology specialization from Riga Stradiņš University. She joined Olainfarm management team in 2022.



**Maksims Vlasenko**

Director of Strategic Development

Maksim, a seasoned pharmaceutical professional, has been advising Olainfarm's Chairman since March 2023, supervising strategic partnerships and product development, with a diverse background including Business development director role at AB City, investment holding owner of Olainfarm. He holds a Masters degree in Business administration, was awarded with certificate of Global Management from INSEAD on June 2023 and completed Clinical Trial Management course at the University of Oxford in 2016.



**Vladimirs Krušinskis**

Director of Technical Department


Vladimirs, with over 20 years of experience in manufacturing companies, currently serves as the Director of the Technical Department at AS "Olainfarm." He joined the company in 2012, previously working at AS "Rīgas Farmacitiskā fabrika." Vladimirs holds a bachelor's degree in engineering.

# Main therapeutical areas

Existing  
therapeutical  
areas




Nervous System



Antibacterial  
agents




Cardiology




Antiallergens

New  
therapeutical  
areas



Anti-Diabetic



Urology



Oncology

# Development of product portfolio



~ 60  
stock keeping units



19  
active pharmaceutical  
ingredients



14  
intermediates




~50  
new products under development  
to expand product portfolio:

- finished dosage forms in key therapeutic areas
- active pharmaceutical ingredients

Olainfarm is Qualified Supplier of Anti- Tuberculosis Medicines to the World Health Organization

\* Figures provided are for December 2022, unless stated otherwise

# Product portfolio expansion pipeline



\* Products approved for portfolio expansion until September 2023



# Prioritized new export regions

## Western Europe:

- 🌐 Germany
- 🌐 Italy
- 🌐 Spain
- 🌐 France
- 🌐 United Kingdom
- 🌐 others

## Middle East and North Africa:

- 🌐 United Arab Emirates
- 🌐 Kingdom of Saudi Arabia

## North America:

- 🌐 USA
- 🌐 Canada

## LATAM:

- 🌐 Mexico
- 🌐 Argentina
- 🌐 Chile

# More than 100 million EUR allocated to the development projects



Product Portfolio  
Development &  
Expansion in New Export  
Markets



Reconstruction of  
Wastewater Treatment  
Systems



Production Modernization,  
Automation, and Capacity  
Enhancement



Green Energy,  
Energy Efficiency  
and Sustainability



Digitalization



Employee Well-being,  
and Further  
Improvements of  
Working Conditions

# Quality Assurance and Certifications

**EU GMP:** Compliant for APIs and FDFs

**U.S. FDA GMP:** Certified for selected APIs

**Australian TDA:** Certified for FDFs

**Turkey GMP:** Certified for FDFs

**Japanese PMDA GMP:** Certified for selected APIs

**ISO 14001:2015:** Environmental responsibility

**ISO/IEC 17025:2017:** Laboratory excellence

**WHO Qualified:** Anti-tuberculosis meds supplier



# Olainfarm's Contribution to the ESG Principles

## E Environmental

28.6% Reduction in Carbon Emissions Over the Past 5 Years.

Implementation of Renewable Energy Sources, Including a 3.2 MWh Solar Panel Park.

Renovation of existing external heating and steam pipelines to reduce carbon emissions (heat losses).

Our target is to invest at least 3 million EUR yearly in environmental and energy efficiency projects until 2027.

New Wastewater Treatment System for Sustainable Water Management.

ISO 14001:2015 Certification for Environmental Responsibility and its supplementation by a continuous energy consumption evaluation process.

## S Social

Active Engagement in Local Communities, Supporting Education, Healthcare, and Science

Employee Well-being Programs, Including Mental Health Support

A Diverse and Inclusive Workforce with 56% Female Representation Among Unit Managers

High Focus on Workplace Safety

## G Governance

Transparent Corporate Governance Practices and Reporting

Strong Ethical Business Standards, Including Anti-Corruption and AML Measures

A Board of Directors Comprising Industry Experts and Thought Leaders

Full Compliance with Regulatory Standards and Regular Audits



**Golden Award in the National Sustainability Index for Two Consecutive Years (2022 and 2023)**

**Taking care of your  
health for more than 50  
years!**



---

[www.olainfarm.lv](http://www.olainfarm.lv)

[olainfarm@olainfarm.com](mailto:olainfarm@olainfarm.com)

Rūpnīcu iela 5, Olaine, Latvia

[www.olainfarm.com](http://www.olainfarm.com)